

## PALM INTRANET

Day : Tuesday  
 Date: 1/13/2004  
 Time: 09:36:31

## Inventor Name Search Result

Your Search was:

Last Name = MADERA

First Name = ANN

Application#	Patent#	Status	Date Filed	Title	Inventor Name 15
<a href="#"><u>60411480</u></a>	Not Issued	020	09/17/2002	2,4-SUBSTITUTED INDOLES	MADERA, ANN MARIE
<a href="#"><u>60411239</u></a>	Not Issued	020	09/17/2002	2,7-SUBSTITUTED INDOLES	MADERA, ANN MARIE
<a href="#"><u>60336795</u></a>	Not Issued	159	12/03/2001	4-PIPERIDINYL ALKYL AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS	MADERA, ANN MARIE
<a href="#"><u>60336675</u></a>	Not Issued	159	12/03/2001	AMINO-TETRALIN DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS	MADERA, ANN MARIE
<a href="#"><u>60267617</u></a>	Not Issued	159	02/09/2001	BENZOCYCLOALKYLENYLAMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS	MADERA, ANN MARIE
<a href="#"><u>60207483</u></a>	Not Issued	159	05/25/2000	HETEROCYCLYALKYLAMINES AS MUSCARINIC RECEPTOR ANTAGONISTS	MADERA, ANN MARIE
<a href="#"><u>10663335</u></a>	Not Issued	020	09/16/2003	2,4-SUBSTITUTED INDOLES AND METHODS OF USE	MADERA, ANN MARIE
<a href="#"><u>10663314</u></a>	Not Issued	020	09/16/2003	2,7-SUBSTITUTED INDOLES	MADERA, ANN MARIE
<a href="#"><u>10632734</u></a>	Not Issued	041	08/01/2003	BENZOCYCLOALKYLENYLAMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS	MADERA, ANN MARIE
<a href="#"><u>10611193</u></a>	Not Issued	041	07/01/2003	4-PIPERIDINYL ALKYL AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS	MADERA, ANN MARIE
<a href="#"><u>10608604</u></a>	Not Issued	030	06/27/2003	AMINO-TETRALIN DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS	MADERA, ANN MARIE

<a href="#">10308092</a>	<a href="#">6635658</a>	150	12/02/2002	AMINO-TETRALIN DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS	MADERA, ANN MARIE
<a href="#">10308081</a>	<a href="#">6627644</a>	150	12/02/2002	4-PIPERIDINYL ALKYL AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS	MADERA, ANN MARIE
<a href="#">10289055</a>	<a href="#">6645958</a>	150	11/06/2002	BENZOCYCLOCALKYLENYLAMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS	MADERA, ANN MARIE
<a href="#">09862522</a>	<a href="#">6500822</a>	150	05/22/2001	BENZOCYCLOCALKYLENYLAMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS	MADERA, ANN MARIE

Inventor Search Completed: No Records to Display.

**Search Another:**

**Inventor**

Last Name

First Name

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | Home page

10/608,604



=> d ibib abs hitstr

STN - Structure  
Search  
1.13.04

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 2003:454291 CAPLUS  
DOCUMENT NUMBER: 139:22114  
TITLE: Preparation of aminotetralin derivatives as muscarinic receptor antagonists  
INVENTOR(S): Madera, Ann Marie; Weikert, Robert James  
PATENT ASSIGNEE(S): F. Hoffmann-La Roche AG, Switz.  
SOURCE: PCT Int. Appl., 57 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003048125	A1	20030612	WO 2002-EP13219	20021125
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003171362	A1	20030911	US 2002-308092	20021202
US 6635658	B2	20031021		

PRIORITY APPLN. INFO.: US 2001-336675P P 20011203  
OTHER SOURCE(S): MARPAT 139:22114  
GI




AB Title compds. I [] are prep'd. For instance, 7-methoxy-3,4-dihydro-1H-

naphthalen-2-one is alkylated with [1-benzylpiperidin-4-yl]amine (ClCH<sub>2</sub>CH<sub>2</sub>Cl, NaHB(OAc)<sub>3</sub>), the resulting product is alkylated with propionaldehyde (ClCH<sub>2</sub>CH<sub>2</sub>Cl, NaHB(OAc)<sub>3</sub>), debenzylated (EtOH, H<sub>2</sub>-Pd(OH)<sub>2</sub>) and acylated with morpholine-4-carbonyl chloride (CH<sub>2</sub>Cl<sub>2</sub>, DIEA) to give II. II has pKi = 8.57 and 8.83 for the muscarinic M<sub>2</sub> and M<sub>3</sub> receptor resp. I are useful for the treatment of smooth muscle disorders and genitourinary diseases.

IT 539828-37-0P, [4-[(7-Methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidin-1-yl]morpholin-4-ylmethanone  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (prepn. of aminotetralin derivs. as muscarinic M<sub>2</sub>/M<sub>3</sub> receptor antagonists)

RN 539828-37-0 CAPLUS

CN Morpholine, 4-[[4-[propyl(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]-1-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



IT 539828-42-7P, 1-[4-[(7-Methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidine-1-carbonyl]piperidin-1-yl]ethanone  
 539828-43-8P, [4-[(7-Methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidin-1-yl][2-methylphenyl]methanone  
 539828-44-9P, [Furan-2-yl][4-[(7-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidin-1-yl]methanone  
 539828-45-0P, 4-[(7-Methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidine-1-carboxylic acid diethylamide  
 539828-46-1P, (3,5-Dimethylisoxazol-4-yl)[4-[(7-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidin-1-yl]methanone  
 539828-47-2P, (4-(Methanesulfonyl)phenyl)[4-[(7-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidin-1-yl]methanone  
 539828-48-3P, [4-[(7-Methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidine-1-carbonyl]phenyl]urea 539828-49-4P,  
 1-[4-[(7-Methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidine-1-carbonyl]phenyl]pyrrolidin-2-one  
 539828-50-7P, [4-[(7-Methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidin-1-yl][4-(1H-tetrazol-5-yl)phenyl]methanone  
 539828-51-8P, N-[4-[(7-Methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidine-1-carbonyl]phenyl]methanesulfonamide  
 539828-52-9P, 4-[(7-Methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidine-1-carboxylic acid methylamide  
 539828-53-0P, 4-[(7-Methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidine-1-carboxylic acid (4-trifluoromethylphenyl)amide  
 539828-54-1P, 4-[(7-Methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidine-1-carboxylic acid (3-cyanophenyl)amide  
 539828-55-2P, 1-[4-[(7-Methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidin-1-yl]ethanone 539828-56-3P,  
 [4-[(7-Methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidin-1-yl]piperazin-1-ylmethanone 539828-57-4P, 4-[(7-Methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidine-1-carboxylic acid isopropylamide 539828-58-5P, 4-[(7-Methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidine-1-carboxylic acid dimethylamide 539828-59-6P, [4-[(7-Methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidin-1-yl]piperidin-4-


ylmethanone 539828-60-9P, [4-[(7-Methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidin-1-yl] (1H-pyrazol-4-yl)methanone 539828-61-0P 539828-62-1P, 4-[(7-Methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidine-1-carboxylic acid N-(piperidin-4-yl)amide 539828-63-2P, [4-[(7-Methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidin-1-yl] (4-methylpiperazin-1-yl)methanone 539828-64-3P, (1H-Imidazol-4-yl) [4-[(7-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidin-1-yl]methanone 539828-65-4P, [[1,4]Diazepan-1-yl] [4-[(7-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidin-1-yl]methanone 539828-66-5P, [4-[(7-Methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidin-1-yl] (1-methylpiperidin-4-yl)methanone 539828-67-6P, [4-[(7-Methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidin-1-yl]piperidin-3-ylmethanone 539828-68-7P, [4-[(6,7-Dimethoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidin-1-yl]piperidin-4-ylmethanone 539828-69-8P, [4-[(6,7-Dimethoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidin-1-yl]morpholin-4-ylmethanone 539828-70-1P, [4-[(6,7-Dimethoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidin-1-yl]piperazin-1-ylmethanone 539828-71-2P, 4-[(6,7-Dimethoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidine-1-carboxylic acid diethylamide 539828-72-3P, [4-[(6,7-Dimethoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidin-1-yl] (4-methylpiperazin-1-yl)methanone 539828-73-4P, [4-[(6,7-Dimethoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidin-1-yl] (1-methylpiperidin-4-yl)methanone 539828-74-5P, [4-[(7-Bromo-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidin-1-yl] [morpholin-4-yl]methanone 539828-78-9P, [4-[(7-Bromo-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidin-1-yl]piperidin-4-ylmethanone 539828-79-0P 539828-80-3P, 4-[(7-Bromo-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidine-1-carboxylic acid dimethylamide 539828-81-4P, (R)-[4-[(7-Methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamino]piperidin-1-yl]piperidin-4-ylmethanone 539828-84-7P, 2-Chlorobenzenesulfonic acid 7-[[1-(morpholine-4-carbonyl)piperidin-4-yl]propylamino]-5,6,7,8-tetrahydronaphthalen-2-yl ester 539828-86-9P, 2,5-Dichlorothiophene-3-sulfonic acid 7-[[1-(morpholine-4-carbonyl)piperidin-4-yl]propylamino]-5,6,7,8-tetrahydronaphthalen-2-yl ester 539828-87-0P, 2-Bromobenzenesulfonic acid 7-[[1-(morpholine-4-carbonyl)piperidin-4-yl]propylamino]-5,6,7,8-tetrahydronaphthalen-2-yl ester 539828-88-1P, 2-Cyanobenzenesulfonic acid 7-[[1-(morpholine-4-carbonyl)piperidin-4-yl]propylamino]-5,6,7,8-tetrahydronaphthalen-2-yl ester 539828-89-2P, 3,5-Dimethylisoxazole-4-sulfonic acid 7-[[1-(morpholine-4-carbonyl)piperidin-4-yl]propylamino]-5,6,7,8-tetrahydronaphthalen-2-yl ester

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aminotetralin derivs. as muscarinic M2/M3 receptor antagonists)


RN 539828-42-7 CAPLUS

CN Piperidine, 1-[(1-acetyl-4-piperidinyl)carbonyl]-4-[propyl(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]- (9CI) (CA INDEX NAME)




RN 539828-43-8 CAPLUS

CN 4-Piperidinamine, 1-(2-methylbenzoyl)-N-propyl-N-(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 539828-44-9 CAPLUS

CN 4-Piperidinamine, 1-(2-furylcarbonyl)-N-propyl-N-(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 539828-45-0 CAPLUS

CN 1-Piperidinecarboxamide, N,N-diethyl-4-[propyl(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]- (9CI) (CA INDEX NAME)




RN 539828-46-1 CAPLUS

CN 4-Piperidinamine, 1-[(3,5-dimethyl-4-isoxazolyl)carbonyl]-N-propyl-N-(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 539828-47-2 CAPLUS

CN 4-Piperidinamine, 1-[4-(methylsulfonyl)benzoyl]-N-propyl-N-(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 539828-48-3 CAPLUS


CN 4-Piperidinamine, 1-[4-[(aminocarbonyl)amino]benzoyl]-N-propyl-N-(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 539828-49-4 CAPLUS


CN 4-Piperidinamine, 1-[4-(2-oxo-1-pyrrolidinyl)benzoyl]-N-propyl-N-(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)

→




RN 539828-50-7 CAPLUS


CN 4-Piperidinamine, N-propyl-N-(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)-1-[4-(1H-tetrazol-5-yl)benzoyl]- (9CI) (CA INDEX NAME)




RN 539828-51-8 CAPLUS  
CN 4-Piperidinamine, 1-[4-[(methylsulfonyl)amino]benzoyl]-N-propyl-N-(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 539828-52-9 CAPLUS  
CN 1-Piperidinecarboxamide, N-methyl-4-[propyl(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]- (9CI) (CA INDEX NAME)



RN 539828-53-0 CAPLUS  
CN 1-Piperidinecarboxamide, 4-[propyl(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 539828-54-1 CAPLUS  
CN 1-Piperidinecarboxamide, N-(3-cyanophenyl)-4-[propyl(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]- (9CI) (CA INDEX NAME)




RN 539828-55-2 CAPLUS

CN 4-Piperidinamine, 1-acetyl-N-propyl-N-(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 539828-56-3 CAPLUS

CN 4-Piperidinamine, 1-(1-piperazinylcarbonyl)-N-propyl-N-(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 539828-57-4 CAPLUS

CN 1-Piperidinecarboxamide, N-(1-methylethyl)-4-[propyl(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]- (9CI) (CA INDEX NAME)




RN 539828-58-5 CAPLUS


CN 1-Piperidinecarboxamide, N,N-dimethyl-4-[propyl(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]- (9CI) (CA INDEX NAME)



RN 539828-59-6 CAPLUS  
CN 4-Piperidinamine, 1-(4-piperidinylcarbonyl)-N-propyl-N-(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 539828-60-9 CAPLUS  
CN 4-Piperidinamine, N-propyl-1-(1H-pyrazol-4-ylcarbonyl)-N-(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 539828-61-0 CAPLUS  
CN Piperazine, 3,5-dimethyl-1-[[4-[propyl(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]-1-piperidinyl]carbonyl]-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 539828-62-1 CAPLUS  
CN 1-Piperidinecarboxamide, N-4-piperidinyl-4-[propyl(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]- (9CI) (CA INDEX NAME)




RN 539828-63-2 CAPLUS

CN Piperazine, 1-methyl-4-[(4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]-1-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 539828-64-3 CAPLUS

CN 4-Piperidinamine, 1-(1H-imidazol-4-ylcarbonyl)-N-propyl-N-(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 539828-65-4 CAPLUS

CN 1H-1,4-Diazepine, hexahydro-1-[(4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]-1-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 539828-66-5 CAPLUS


CN 4-Piperidinamine, 1-[(1-methyl-4-piperidinyl)carbonyl]-N-propyl-N-(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



10/608,604


RN 539828-67-6 CAPLUS

CN 4-Piperidinamine, 1-(3-piperidinylcarbonyl)-N-propyl-N-(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 539828-68-7 CAPLUS

CN 4-Piperidinamine, 1-(4-piperidinylcarbonyl)-N-propyl-N-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 539828-69-8 CAPLUS

CN Morpholine, 4-[[4-[propyl(1,2,3,4-tetrahydro-6,7-dimethoxy-2-naphthalenyl)amino]-1-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 539828-70-1 CAPLUS

CN Piperazine, 1-[[4-[propyl(1,2,3,4-tetrahydro-6,7-dimethoxy-2-naphthalenyl)amino]-1-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 539828-71-2 CAPLUS

CN 1-Piperidinecarboxamide, N,N-diethyl-4-[propyl(1,2,3,4-tetrahydro-6,7-dimethoxy-2-naphthalenyl)amino]- (9CI) (CA INDEX NAME)




RN 539828-72-3 CAPLUS

CN Piperazine, 1-methyl-4-[(4-[(1,2,3,4-tetrahydro-6,7-dimethoxy-2-naphthalenyl)amino]-1-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 539828-73-4 CAPLUS

CN 4-Piperidinamine, 1-[(1-methyl-4-piperidinyl)carbonyl]-N-propyl-N-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 539828-74-5 CAPLUS

CN Morpholine, 4-[(4-[(7-bromo-1,2,3,4-tetrahydro-2-naphthalenyl)propylamino]-1-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 539828-78-9 CAPLUS


CN 4-Piperidinamine, N-(7-bromo-1,2,3,4-tetrahydro-2-naphthalenyl)-1-(4-piperidinylcarbonyl)-N-propyl- (9CI) (CA INDEX NAME)



RN 539828-79-0 CAPLUS


CN Piperazine, 1-[(4-[(7-bromo-1,2,3,4-tetrahydro-2-naphthalenyl)propylamino]-1-piperidinyl)carbonyl]-3,5-dimethyl-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 539828-80-3 CAPLUS


CN 1-Piperidinecarboxamide, 4-[(7-bromo-1,2,3,4-tetrahydro-2-naphthalenyl)propylamino]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 539828-81-4 CAPLUS


CN 4-Piperidinamine, 1-(4-piperidinylcarbonyl)-N-propyl-N-[(2R)-1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 539828-84-7 CAPLUS


CN Benzenesulfonic acid, 2-chloro-, 5,6,7,8-tetrahydro-7-[(1-(4-morpholinylcarbonyl)-4-piperidinyl)propylamino]-2-naphthalenyl ester (9CI) (CA INDEX NAME)




RN 539828-86-9 CAPLUS  
CN 3-Thiophenesulfonic acid, 2,5-dichloro-, 5,6,7,8-tetrahydro-7-[(1-(4-morpholinylcarbonyl)-4-piperidinyl)propylamino]-2-naphthalenyl ester (9CI)  
(CA INDEX NAME)




RN 539828-87-0 CAPLUS  
CN Benzenesulfonic acid, 2-bromo-, 5,6,7,8-tetrahydro-7-[(1-(4-morpholinylcarbonyl)-4-piperidinyl)propylamino]-2-naphthalenyl ester (9CI)  
(CA INDEX NAME)



RN 539828-88-1 CAPLUS  
CN Benzenesulfonic acid, 2-cyano-, 5,6,7,8-tetrahydro-7-[(1-(4-morpholinylcarbonyl)-4-piperidinyl)propylamino]-2-naphthalenyl ester (9CI)  
(CA INDEX NAME)




RN 539828-89-2 CAPLUS  
CN 4-Isoxazolesulfonic acid, 3,5-dimethyl-, 5,6,7,8-tetrahydro-7-[(1-(4-morpholinylcarbonyl)-4-piperidinyl)propylamino]-2-naphthalenyl ester (9CI)  
(CA INDEX NAME)



IT 539828-85-8P, [4-[(7-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylaminolpiperidin-1-yl]morpholin-4-ylmethanone  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. of aminotetralin derivs. as muscarinic M2/M3 receptor antagonists)

RN 539828-85-8 CAPLUS

CN Morpholine, 4-[(4-[(1,2,3,4-tetrahydro-7-hydroxy-2-naphthalenyl)amino]-1-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d re 1-4

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN  
 RE  
 (1) Ciba Geigy Ag; EP 0532456 A 1993 CAPLUS  
 (2) Hoffmann La Roche; WO 0190082 A 2001 CAPLUS  
 (3) Schering Corp; WO 9800412 A 1998 CAPLUS  
 (4) Schering Corp; WO 9801425 A 1998 CAPLUS

=> d his


(FILE 'HOME' ENTERED AT 09:32:38 ON 13 JAN 2004)

FILE 'REGISTRY' ENTERED AT 09:32:51 ON 13 JAN 2004  
 L1 STRUCTURE uploaded  
 L2 1 S L1  
 L3 44 S L1 FULL

FILE 'CAPLUS' ENTERED AT 09:33:22 ON 13 JAN 2004  
 L4 1 S L3

=> d 11

L1 HAS NO ANSWERS  
 L1 STR



G1 N, CY, Ak

G2 O, X

G3 H, O

Structure attributes must be viewed using STN Express query preparation.